EBSCN(SH:601788) 中国基金报·2025-10-13 14:36Core Viewpoint - The article discusses the withdrawal of Shanghai Guangda Securities Asset Management Co., Ltd. (Guangzheng Asset Management) from the public fund management license application process, highlighting a trend among securities asset management companies in China to pause their public fund license applications [2][6]. Group 1: License Application Status - Guangzheng Asset Management has been removed from the list of institutions applying for public fund management qualifications as per the latest announcement from the China Securities Regulatory Commission (CSRC) [6]. - In August 2023, another asset management company, GF Asset Management, also withdrew from the qualification approval list, leaving only Anxin Asset Management (now Guozheng Asset Management) and Guojin Asset Management still in the application queue [2][6]. Group 2: Historical Context and Regulatory Changes - Guangzheng Asset Management submitted its application for a public fund license on June 19, 2023, and provided supplementary materials on June 27, 2023. However, the application did not enter the formal review stage, and the company did not receive further inquiries from regulators [5][6]. - Since the implementation of new regulations in May 2022, which allow securities firms to hold one public fund license, there have been no new approvals for public fund licenses among securities asset management companies after the licenses were granted to招商资管 and 兴证资管 in 2023 [6]. Group 3: Company Performance and Management Changes - Guangzheng Asset Management reported a revenue of 675 million yuan and a net profit of 219 million yuan for the year 2024, with a total asset management scale of 3,114 billion yuan, reflecting a growth of 3.71% from the beginning of the year [8]. - The company has experienced significant changes in its executive team, raising concerns about its future strategic direction. Notable changes include the departure of the original general manager in January 2023 and subsequent appointments and adjustments within the management team throughout 2024 [8].